Elizabeth C. Paver

Elizabeth C. Paver

Auto-generated profile, based on publicly available information

Elizabeth C. Paver

Melanoma Institute Australia, The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Pathology
Verified
Journal Article
Closed access
EPElizabeth C. Paver
Elizabeth C. Paver
WCWendy A. Cooper
Wendy A. Cooper
ACAndrew J. Colebatch
Andrew J. Colebatch
PFPeter M. Ferguson
Peter M. Ferguson
SHSean K. Hill
Sean K. Hill
RGRuta Gupta
Ruta Gupta

12 December 2023 in Pathology
Verified
Journal Article
Closed access
EPElizabeth C. Paver
Elizabeth C. Paver
AMAdrienne L. Morey
Adrienne L. Morey

30 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
IVIsmael A. Vergara
Ismael A. Vergara
NMNigel G. Maher
Nigel G. Maher
APAlison J. Potter
Alison J. Potter
EPElizabeth C. Paver
Elizabeth C. Paver
JCJordan Conway
Jordan Conway
Richard A ScolyerRichard A Scolyer
Richard A Scolyer
Purpose: Pathologic diagnosis of melanocytic tumors can be difficult and prone to error. More accurate ancillary tools are needed. We present a genomic model for distinguishing benign (nevi) from malignant (melanoma) melanocytic skin tumors. Experimental Design: A DNA-based gene panel was evaluated on 250 nevi and melanomas, split into discovery and validation sets. Mutational loads were calculated, and a logistic regression model was developed and validated. An independent cohort of 110 borderline melanocytic tumors was analyzed against pathology-based tiers of malignancy and likely pathways of origin. Results: Combining non-BRAF/non-NRAS coding mutational load and noncoding mutational load, we obtained an AUC of 95% in the discovery and 96% in the validation cohort. Using a Youden index threshold, the resulting classifier demonstrated >95% specificity and >80% sensitivity in the discovery and validation cohorts. In the cohort of 110 borderline melanocytic tumors, we identified key driver mutations in agreement with the likely pathway of origin. Noncoding mutational load (P = 0.02) and melanoma probability (P = 0.02) from the genomic model were significantly associated with malignancy estimates in borderline tumors lacking pathway-defining genomic aberrations (conventional tumors). The genomic model estimated a high probability of melanoma in 8 of 36 (22%) conventional tumors with indeterminate malignancy, with 7 of 8 showing negative/nonaberrant results on other ancillary diagnostic tests. No malignant behavior based on the genomic model was seen in four conventional borderline tumors with >1 year of follow-up. Conclusions: This genomic model can become a clinically useful ancillary tool that is highly specific for differentiating melanomas from nevi.

29 March 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
GHG. Ho
G. Ho
RSR.J. Schwartz
R.J. Schwartz
APA. Regio Pereira
A. Regio Pereira
FDF. Dimitrou
F. Dimitrou
EPE. Paver
E. Paver
PGP. Guitera
P. Guitera

2 September 2025
Verified
Other
Open access
PDF file
IVIsmael A. Vergara
Ismael A. Vergara
NMNigel G. Maher
Nigel G. Maher
APAlison J. Potter
Alison J. Potter
EPElizabeth C. Paver
Elizabeth C. Paver
JCJordan Conway
Jordan Conway
Richard A ScolyerRichard A Scolyer
Richard A Scolyer
Distribution of total, coding and non-coding mutational load against pathological and clinical features. (A) Distribution in melanomas. (B) Distribution in nevi. LOESS regression is shown in blue for thickness, TMR and age at biopsy. NS: Not significant. (*): p-value<0.05. (**): p-value<0.01. (***): p-value<0.001.

2 September 2025
Verified
Other
Open access
IVIsmael A. Vergara
Ismael A. Vergara
NMNigel G. Maher
Nigel G. Maher
APAlison J. Potter
Alison J. Potter
EPElizabeth C. Paver
Elizabeth C. Paver
JCJordan Conway
Jordan Conway
Richard A ScolyerRichard A Scolyer
Richard A Scolyer
Patients with borderline conventional tumors and available clinical followup